{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Khoury P"],"funding":["National Center for Advancing Translational Sciences","NCATS NIH HHS","International Eosinophil Society, AstraZeneca, and GlaxoSmithKline","NIAID NIH HHS","NHLBI NIH HHS","National Fund for Scientific Research","Division of Intramural Research"],"pagination":["307-320"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11271980"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["116(2)"],"pubmed_abstract":["Rare eosinophil-associated disorders (EADs), including hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, and eosinophilic gastrointestinal disorders, are a heterogeneous group of conditions characterized by blood and/or tissue hypereosinophilia and eosinophil-related clinical manifestations. Although the recent availability of biologic therapies that directly and indirectly target eosinophils has the potential to dramatically improve treatment options for all EADs, clinical trials addressing their safety and efficacy in rare EADs have been relatively few. Consequently, patient access to therapy is limited for many biologics, and the establishment of evidence-based treatment guidelines has been extremely difficult. In this regard, multicenter retrospective collabora"],"journal":["Journal of leukocyte biology"],"pubmed_title":["Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities."],"pmcid":["PMC11271980"],"funding_grant_id":["R56 AI121186","U19 AI136443","K23 AI171085","G0H1222N","R01 AI168134","54372"],"pubmed_authors":["Brister D","O'Riordan T","Goddard J","Kim TB","Munitz A","Ueki S","Baatjes A","Oladipo O","Zimmermann N","Wright B","Chhiba K","Carstens D","Johansson MW","Li Kuang F","Spencer LA","Kwiatek J","Lee JH","Prussin C","Kuang FL","Amber K","Menzies-Gow A","Simon HU","Kita H","Levi-Schaffer F","Bochner B","Masterson J","Ackerman S","Spencer L","Coussement G","Rothenberg M","Bochner BS","Hogan N","Kahn JE","Fulkerson P","Mok A","Furuta G","Maric I","International Eosinophil Society Clinical Research Interest Group","Kovalszki A","Roufosse F","Drake M","Weller P","Mathur SK","Ogbogu P","Llanos JP","Khoury P","Ackerman SJ","Diab N","Akuthota P","Karimi S","Bahadori L","Denburg J","Fryer A","Catherine J","Gleich G","Carpentier C","Nader L","Brunet L","Wechsler ME","Mathur S","Orlandini K","Shiraishi Y","Klion AD","Jacobsen E","Minnicozzi M","Montizaan D","Baylis L","Leiferman K","Klion A","Gauvreau G","Groh M","Smith S","Wechsler M","Ogbogu PU","Melhorn J","Shi GP","Baudy P","Chevalier K","Johansson M","Cook-Mills J","Simon D","Friend W"],"additional_accession":[]},"is_claimable":false,"name":"Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities.","description":"Rare eosinophil-associated disorders (EADs), including hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, and eosinophilic gastrointestinal disorders, are a heterogeneous group of conditions characterized by blood and/or tissue hypereosinophilia and eosinophil-related clinical manifestations. Although the recent availability of biologic therapies that directly and indirectly target eosinophils has the potential to dramatically improve treatment options for all EADs, clinical trials addressing their safety and efficacy in rare EADs have been relatively few. Consequently, patient access to therapy is limited for many biologics, and the establishment of evidence-based treatment guidelines has been extremely difficult. In this regard, multicenter retrospective collabora","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-07-15T12:55:02.606Z","creation":"2025-04-19T13:12:35.907Z"},"accession":"S-EPMC11271980","cross_references":{"pubmed":["38457125"],"doi":["10.1093/jleuko/qiae051"]}}